Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Gadopiclenol (Primary) ; Gadobutrol
- Indications Advanced breast cancer; CNS disorders; Head and neck cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Uterine cancer
- Focus Diagnostic use; Registrational
- Acronyms PROMISE
- Sponsors Guerbet
- 11 Dec 2023 According to a Guerbet media release, Primary endpoint (Lesion visualization criteria for gadopiclenol-enhanced MRI compared to gadobutrol-enhanced MRI)has been met.
- 11 Dec 2023 According to a Guerbet media release, Primary endpoint (Lesion visualization criteria for gadopiclenol-enhanced MRI compared to unhenhanced MRI) has been met.
- 11 Dec 2023 According to a Guerbet media release, the marketing authorisation (MA) for Elucirem (Gadopiclenol) was granted for use in contrast-enhanced magnetic resonance imaging (MRI) to Guerbet by the European Commission based on the positive opinion of the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP).